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A B S T R A C T
Dermal immunization using antigen-coated microneedle arrays is a promising vaccination strategy. However,
reduction of microneedle sharpness and the available surface area for antigen coating is a limiting factor. To
overcome these obstacles, a layer-by-layer coating approach can be applied onto pH-sensitive microneedles.
Following this approach, pH-sensitive microneedle arrays (positively charged at coating pH 5.8 and nearly
uncharged at pH 7.4) were alternatingly coated with negatively charged diphtheria toxoid (DT) and N-trimethyl
chitosan (TMC), a cationic adjuvant. First, the optimal DT dose for intradermal immunization was determined in
a dose-response study, which revealed that low-dose intradermal immunization was more eﬃcient than sub-
cutaneous immunization and that the EC50 dose of DT upon intradermal immunization is 3-fold lower, as
compared to subcutaneous immunization. In a subsequent immunization study, microneedle arrays coated with
an increasing number (2, 5, and 10) of DT/TMC bilayers resulted in step-wise increasing DT-speciﬁc immune
responses. Dermal immunization with microneedle arrays coated with 10 bilayers of DT/TMC (corresponding
with± 0.6 μg DT delivered intradermally) resulted in similar DT-speciﬁc immune responses as subcutaneous
immunization with 5 μg of DT adjuvanted with aluminum phosphate (8-fold dose reduction). Summarizing, the
layer-by-layer coating approach onto pH-sensitive microneedles is a versatile method to precisely control the
amount of coated and dermally-delivered antigen that is highly suitable for dermal immunization.
1. Introduction
Intradermal immunization has several beneﬁts over conventional
immunization by intramuscular bolus injection, as the skin is easily
accessible and intradermal immunization is potentially pain-free.
Moreover, superior immunization responses resulting from intradermal
immunization as compared to conventional intramuscular immuniza-
tion were reported for hepatitis B [1,2], inﬂuenza [3–8] and polio
[9–11]. This may be caused by the specialized dendritic cell subsets that
are present in high numbers in the skin [12]. To deliver a suﬃcient
amount of antigen to these cells, the physical barrier of the skin, the
stratum corneum, must be overcome [13]. For this purpose micro-
needles can be used, which are needle-like structures used to pierce the
stratum corneum in a minimally-invasive way. Several technologies for
microneedle-mediated vaccine delivery are under development [14],
such as coated microneedle arrays.
The amount of antigen delivery by coated microneedle arrays may
be limited, because of the limited surface area available for coating.
Therefore, diﬀerent approaches have been developed to increase the
amount of coated antigen. For example, dipping low-density micro-
needle arrays in an antigen-containing viscous solution leads to thick
coatings containing a high amount of antigen (2 μg) [15,16]. However,
applying the dip-coating technique to high-density microneedle arrays
results in blunting of the microneedles, which may impair the skin
penetration ability of the microneedles [15,17–19].
An alternative coating approach resulting in a thin coating is to
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modify the microneedle surface to control the antigen coating onto
microneedle arrays and subsequent release into the skin by pH-depen-
dent electrostatic interactions. In this approach, a negatively charged
antigen adheres to a microneedle surface that is positively charged at a
coating pH of 5.8. Upon piercing these antigen-coated pH-sensitive
microneedles into skin, the electrostatic interactions between the an-
tigen and the microneedles surface cease. This is caused by shifting the
pH from a slightly acidic one (of the coating solution) towards a slightly
alkaline one (physiological pH (7.4) of the skin). This pH-change in-
duces a change in microneedle surface charge from positive to neutral,
respectively [20]. Such pH-sensitive microneedle surface modiﬁcations
allow to eﬃciently coat thin layers of antigens onto high-density mi-
croneedle arrays and for a controllable and eﬀective antigen delivery.
However, the limitation of this manner of antigen-coating is that
only low amounts of antigens can be coated onto microneedle arrays.
This limitation can be overcome by using a layer-by-layer coating ap-
proach [21–23]. To eﬀectively increase the amount of antigen coated
onto microneedle arrays, multiple layers of antigen and polymer are
stacked onto one another, utilizing electrostatic interactions between
antigen and polymer. Using this approach, high-density microneedle
arrays were successfully coated with inactivated polio vaccine (IPV)
particles and the adjuvant N-trimethyl chitosan (TMC) [24]. However,
this approach was not yet examined for subunit vaccines such as
diphtheria toxoid (DT), which is used in all pediatric vaccination pro-
grams worldwide.
In this study, a layer-by-layer coating approach of DT (a negatively
charged antigen above a pH of 5) and the adjuvant TMC (a positively
charged polymeric adjuvant) on high-density microneedle arrays
modiﬁed with a pH-sensitive microneedle-surface was developed. It
was demonstrated that the amount of DT coated onto the microneedle
array was reproducible and the dermally-delivered amount of antigen
was tuned by selecting the number of coated DT/TMC bilayers.
Furthermore, the DT/TMC-coated microneedle arrays were capable of
inducing potent and functional DT-speciﬁc immune responses upon
dermal application in mice.
2. Materials
The materials are provided in Supplementary data S1.
3. Methods
3.1. Preparation of ﬂuorescently labeled DT, aluminum phosphate-adsorbed
DT and (ﬂuorescently labeled) TMC
To visualize DT and/or TMC adhesion to microneedle arrays and
release into skin, DT and TMC were ﬂuorescently labeled. DT was
ﬂuorescently labeled with AlexaFluor® 488 (DT-AF488) according to
the manufacturer's protocol. TMC with a 15% quaternization degree
was synthesized as described elsewhere [25], and was ﬂuorescently
labeled with rhodamine B isothiocyanate (TMC-RHO) as previously
reported [26]. To quantify the delivery of DT into skin, DT was ﬂuor-
escently labeled with a near-infrared ﬂuorescent label IRDye® 800CW
(DT-IRDYE800) according to the manufacturer's protocol. Aluminum
phosphate-adsorbed DT (DT-ALUM) was prepared in a DT:alum ratio of
1:30 (w/w) and the adsorption was between 70 and 80% as determined
by a DT-speciﬁc ELISA, as described elsewhere [27].
3.2. DT/TMC layer-by-layer coating approach for high-density microneedle
arrays
To coat DT and TMC onto high-density microneedle arrays via a
layer-by-layer coating approach, the following procedures were used.
High-density silicon microneedle arrays with 576 microneedles on a
5 × 5 mm backplate (microneedle density of 2304 microneedles/cm2)
and a microneedle length of 220 μm were kindly provided by Robert
Bosch GmbH (Stuttgart, Germany). In order to produce pH-sensitive
microneedle surfaces with a surface pKa of 6.9, the surfaces of micro-
needle arrays were chemically modiﬁed with a pyridine functional
group, as explained in detail elsewhere [20,24]. Consequently, at a
coating pH of 5.8, the microneedle surfaces are positively charged,
while (unlabeled and ﬂuorescently labeled) DT is negatively charged
and (unlabeled and ﬂuorescently labeled) TMC is positively charged.
Subsequently, a layer-by-layer coating approach was used to coat
multiple layers of negatively charged DT and positively charged TMC
by electrostatic interactions onto the microneedle arrays, as schemati-
cally represented in Fig. 1. Optimization of the coating procedure is
described in Supplementary data S2. Some studies required the mi-
croneedle arrays to be coated with ﬂuorescently labeled DT and ﬂuor-
escently labeled TMC. For these studies, plain DT was replaced by either
ﬂuorescently labeled DT-AF488 or DT-IRDYE800 and plain TMC was
replaced by ﬂuorescently labeled TMC-RHO. The ﬂuorescence of (un-
labeled and ﬂuorescently labeled) DT and ﬂuorescently labeled TMC
was measured on a Tecan Inﬁnite M1000 plate reader (Männedorf,
Switzerland) at excitation and emission wavelengths shown in Table 1.
Fig. 1. Schematic illustration of the layer-by-layer coating
approach of pH-sensitive microneedle surfaces.
To make use of the electrostatic interactions in the layer-by-
layer coating approach, a 1 mM EDTA buﬀer at pH 5.8 was
used as coating buﬀer, with DT or TMC in a concentration
of 40 μg/mL. The ﬁrst layer of DT was coated by applying a
50 μL droplet of the DT solution onto the pH-sensitive
surface of the microneedle array for 30 min at room tem-
perature. Then, the microneedle arrays were washed with
450 μL coating buﬀer. Subsequently, the microneedle ar-
rays were dried under a ﬂow of nitrogen gas. After drying, a
layer of TMC was applied onto the DT-coated surface of the
microneedle array, followed by washing and drying, as
described above. Then a subsequent DT/TMC bilayer was
coated onto the surface of the microneedle arrays, as de-
scribed above, until the preselected number of DT/TMC
bilayers was coated onto the microneedle arrays. The amount of coated DT or TMC, was determined by measuring the ﬂuorescence of DT or ﬂuorescently labeled DT-AF488, DT-
IRDYE800 or TMC-RHO in the non-adhered fraction in each of the wash samples.
Table 1
Excitation and emission wavelengths of DT and TMC used for ﬂuorimetric assays (for
details, see Methods section).
Compound Fluorescence Excitation wavelength
(nm)
Emission wavelength
(nm)
DT Intrinsic 280 320
DT-AF488 Extrinsic 490 525
DT-IRDYE800 Extrinsic 774 789
TMC-RHO Extrinsic 550 580
P. Schipper et al. Journal of Controlled Release 262 (2017) 28–36
29
3.3. Scanning electron microscopy (SEM) and confocal laser scanning
microscopy (CLSM) imaging of DT/TMC coated microneedle arrays
SEM imaging of DT/TMC coated microneedle arrays was performed
to inspect the microneedle tip sharpness, geometry and surface mor-
phology of the microneedles on a FEI NOVA nanoSEM 200 in high-
voltage mode (10.0 kV). To this end, 4 microneedle arrays coated with
5 bilayers of DT/TMC and as control, 4 microneedle arrays with only a
pH-sensitive surface (plain microneedle arrays) were imaged.
To visualize the distribution of DT and TMC on the surface of DT/
TMC coated microneedles, CLSM imaging of microneedle arrays coated
with 5 bilayers of ﬂuorescently labeled DT-AF488/TMC-RHO was per-
formed. CLSM was performed by utilizing a Nikon TE2000-E inverted
microscope and a Nikon C1 confocal unit (Amsterdam, The
Netherlands), in conjunction with a Nikon CFI Plan-Apochromat λ DM
20× (numerical aperture 0.75) objective. An argon laser (488 nm, laser
intensity 75 and gain 106) and a 515/30 nm emission ﬁlter were used
to visualize ﬂuorescently labeled DT-AF488, while a diode-pumped
solid-state laser (561 nm, laser intensity 75 and gain 95) and a 590/
50 nm emission ﬁlter were used to visualize ﬂuorescently labeled TMC-
RHO. Nikon NIS Elements software version 4.20.00 was utilized for
scan acquisition and analysis. The xy resolution was 1.10 μm/pixel and
xyz scans were taken in steps of 2 μm.
3.4. Antigenicity and structural integrity of coated DT
To assess whether coated DT remained antigenic, DT or ﬂuores-
cently labeled DT-AF488 released in vitro from 4 microneedle arrays
coated with 5 bilayers of DT/TMC or DT-AF488/TMC-RHO, was ex-
amined by DT-speciﬁc ELISA or ﬂuorescence measurements, respec-
tively. To assess the structural integrity of coated DT, the integrity of in
vitro released DT-AF488 was determined by measuring the molecular
weight by non-reducing SDS-PAGE. In vitro release was triggered by
submerging DT/TMC coated microneedles in release buﬀer (5 mM
EDTA with 0.9% (w/v) sodium chloride) at pH 7.4, which induces a
change to a (nearly) neutral surface charge on the pH-sensitive micro-
needle surfaces, loss of electrostatic interactions of the DT/TMC bi-
layers with the microneedle surface and subsequently release of DT and
TMC, as explained in detail elsewhere [20]. More detailed procedures
for this experiment are provided in Supplementary data S3.
3.5. Delivery of DT/TMC into the skin by DT/TMC coated microneedle
arrays
3.5.1. Visualization of ﬂuorescently labeled DT-AF488/TMC-RHO delivery
into human skin
Human skin was obtained from a local hospital and prepared as
described in Supplementary data S4. To examine whether ﬂuorescently
labeled DT-AF488 and TMC-RHO can be delivered into human skin by
coated microneedle arrays, microneedle arrays coated with 5 bilayers of
ﬂuorescently labeled DT-AF488/TMC-RHO were applied onto ex vivo
human skin ﬁxed on Styrofoam, by impact insertion using an in-house
designed microneedle applicator. An average insertion speed of 0.5 m/s
by the microneedle applicator was set on a uPRAX Microsolutions mi-
croneedle applicator controller (The Hague, The Netherlands). After
insertion, the microneedle arrays were ﬁxed onto the skin by applying a
force of 5 N on top of the microneedle array. After 90 min, the micro-
needle arrays were withdrawn from the skin and immediately prepared
for CLSM imaging by ﬁxing the skin in a sample holder. The skin was
imaged by CLSM using the same equipment as described above, except
that a Nikon CFI Plan-Apochromat λ 4× (numerical aperture 0.2)
objective was used. A laser intensity of 75 and gain 95 for the 488 nm
laser were used to visualize ﬂuorescently labeled DT-AF488, while a
laser intensity of 75 and gain 86 for the 561 nm laser were used to
visualize ﬂuorescently labeled TMC-RHO. The xy resolution was
5.18 μm/pixel and xyz scans were taken in steps of 5 μm. The focal
plane of the scans was parallel to the surface of the skin.
3.5.2. Quantiﬁcation of dermally-delivered DT
To study the eﬀect of the number of DT/TMC bilayers on the der-
mally-delivered DT dose, microneedle arrays coated with an increasing
number of ﬂuorescently labeled DT-IRDYE800/TMC bilayers were ap-
plied onto ex vivo human or mouse skin. The delivered DT dose was
quantiﬁed by using an intradermally injected calibration curve.
For this purpose, an in-house developed system consisting of a
single hollow microneedle and a hollow microneedle applicator was
used in conjunction with a uPRAX microneedle applicator controller
and a syringe pump (NE-300, Prosense, Oosterhout, The Netherlands).
This system allowed for intradermal microinjections at a pre-de-
termined skin depth and an accurate volume [10]. The near-infrared
ﬂuorescence of the delivered DT-IRDYE800 was measured in a Perkin-
Elmer IVIS Lumina Series III in vivo imaging system (Waltham, MA,
USA), by using a 745 nm excitation wavelength and an ICG emission
ﬁlter, acquisition time 4 s, F-stop 2, binning 4 and ﬁeld of view of
12.5 cm. Perkin-Elmer Living Image software version 4.3.1.0 was used
for image acquisition and analysis. Background measurements were
taken from control regions of the skin.
Quantiﬁcation of DT delivered into ex vivo human skin by DT/TMC
coated microneedle arrays was performed as follows. Microneedle ar-
rays coated with 5 bilayers of ﬂuorescently labeled DT-IRDYE800/TMC
were applied onto ex vivo human skin for a period of either 30 or
90 min. A calibration curve in ex vivo human skin was obtained by
intradermal microinjections with an injection volume varying between
0.5 and 20 μL at a DT-IRDYE800 concentration of 150 μg/mL and at an
injection depth of 150 μm.
As all immunization studies were performed in mice, quantiﬁcation
of DT delivered by DT/TMC coated microneedle arrays into ex vivo
mouse skin was also examined. Microneedle arrays coated with either
1, 2, 5, 10 or 20 bilayers of ﬂuorescently labeled DT-IRDYE800/TMC
were applied onto ex vivo mouse skin for a period of 90 min. A cali-
bration curve in ex vivo mouse skin was obtained by intradermal mi-
croinjections with injection volumes varying between 0.1 and 10 μL at a
DT-IRDYE800 concentration of 300 μg/mL and at an injection depth of
150 μm.
3.6. Immunization studies
Animal studies were performed in compliance with the guidelines
and regulations enforced by Dutch laws and the Dutch animal ethic
committee. These studies were approved by the
“Dierexperimentencommissie Universiteit Leiden” under number
14166. Female BALB/c (BALB/cAnNCrl, strain code 028, 6 weeks of age
on arrival) were obtained from Charles River, Saint-Germain-sur-
l'Arbresle, France. The mice were housed in groups of 4 in a controlled
environment subjected to the guidelines of the animal facilities of the
Leiden Academic Centre for Drug Research, Leiden University. The
mice were randomly assigned to the immunization groups (8 animals
per group) and were ﬁrst acclimatized for 2 weeks after arrival before a
study started.
3.6.1. Dose-response study of intradermally- and subcutaneously-delivered
DT
To determine the required amount of DT to be delivered by the DT/
TMC coated microneedle arrays for suﬃcient DT-speciﬁc immune re-
sponses, a DT dose-response study was performed. DT-speciﬁc immune
responses were determined after intradermal or subcutaneous im-
munization. DT doses ranging between 0.02 and 5 μg were examined.
Detailed experimental descriptions are provided in Supplementary data
S5.
3.6.2. Immunization study with DT/TMC coated microneedle arrays
The potential for a dermally applied DT/TMC coated microneedle
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array to induce DT-speciﬁc immune responses was investigated and
compared to immunization by an intradermal injection with a single
hollow microneedle or a subcutaneous injection. All immunization
groups are provided in Table 2.
Immunization was performed at day 1 (prime immunization), day
22 (boost immunization) and day 43 (2nd boost immunization). One
day prior to immunization by a DT/TMC coated microneedle array or a
single hollow microneedle, the mice were shaved (an area of 4 cm2 on
the left posterior ﬂank). Serum was collected from each mouse one day
prior to immunization. Venous blood (200 μL) was drawn by tail vein
incision and was collected in a 0.8 mL MiniCollect® tube, which was
stored on ice before centrifugation at 3000g at room temperature for
10 min to isolate serum. At day 63, all mice were sacriﬁced and bled by
incision of the hind leg main artery. This blood was collected in 2.5 mL
Vacuette® tubes and stored on ice before centrifugation at 2000g at
room temperature for 10 min to isolate serum. Sera were stored at
−80 °C until analysis. All mice were immobilized for 90 min by an-
esthesia with 1% isoﬂurane (with 100% oxygen as carrier gas) prior to
and during immunization. During anesthesia, the eyes of the mice were
protected by oculentum simplex.
The following immunization procedures were included in the study:
(1) Dermal immunization was performed by applying a microneedle
array coated with 2, 5 or 10 bilayers of DT/TMC to the skin. The
selected number of coated DT/TMC bilayers was based on two
factors: i) the DT-speciﬁc immune responses resulting from DT
delivered into the skin by a single hollow microneedle as observed
in the DT dose-response study and ii) the amount of ﬂuorescently
labeled DT-IRDYE800 delivered by microneedle arrays coated with
2, 5 and 10 bilayers into ex vivo mouse skin. The DT/TMC coated
microneedle arrays were applied onto shaved mouse skin at a speed
of 0.5 m/s by the in-house designed impact insertion microneedle
applicator in conjunction with a uPRAX microneedle applicator
controller and were held in the skin with dermal tape and a spe-
cially designed clothespin for 90 min.
(2) As control to the dermal immunization with a DT/TMC coated
microneedle array, intradermal immunization by microinjection
with a single hollow microneedle was performed with i) 0.31 μg DT
and ii) 0.31 μg DT mixed with 0.31 μg TMC, using an injection
volume of 10 μL at injection depth of 150 μm. The injected DT dose
was based on the amount of ﬂuorescently labeled DT-IRDYE800
delivered by a microneedle array coated with 5 bilayers into ex vivo
mouse skin. The TMC dose was based on the nearly 1:1 coating ratio
of DT and TMC. The intradermal microinjections were performed as
described above.
(3) As controls to the (intra-)dermal immunization, a group of mice
received subcutaneous injections of 100 μL via a conventional 26G
hypodermic needle of i) 0.31 μg DT ii) 5 μg DT and 150 μg AlPO4
(DT-ALUM) as positive control or iii) phosphate buﬀered saline
(PBS) pH 7.4 as mock treatment.
3.7. Determination of DT-speciﬁc serum IgG titers and diphtheria toxin-
neutralizing antibody titers
To measure DT-speciﬁc total IgG, IgG1 and IgG2a titers in serum, an
ELISA was performed, of which a detailed description of the procedures
is provided in Supplementary data S6. Determination of the antibody
titer capable of neutralizing active diphtheria toxin (DTx) was per-
formed as described elsewhere [27].
3.8. Statistical analysis
Graphs were plotted as mean (± SEM or± 95% conﬁdence in-
terval for the immunization studies) and statistics were performed by
using GraphPad Prism (v.7.00, GraphPad Software, LaJolla, CA, USA).
To statistically compare groups amongst each other, Kruskall-Wallis
tests with Dunn's post-hoc tests were performed because DT-speciﬁc IgG
midpoint titers and DTx neutralizing antibody titers were non-normally
distributed. Diﬀerences were considered signiﬁcant at p < 0.05.
4. Results
4.1. DT/TMC layer-by-layer coating approach for high-density microneedle
arrays
Variations in the coating procedure were examined in order to
maximize the amount of coated DT for each individual bilayer (see
Supplementary data S2 for details). The optimal DT and TMC coating
concentrations were 40 μg/mL, which were used for further experi-
ments.
To determine whether an increased number of coated DT/TMC
layers resulted in an increased amount of coated DT and TMC, micro-
needle arrays were coated with up to 30 bilayers of ﬂuorescently la-
beled DT-AF488 and TMC-RHO. As shown in Fig. 2, 30 bilayers of DT-
AF488/TMC-RHO were successfully coated onto the microneedle arrays
and the amount of coated DT-AF488 and TMC-RHO increased linearly
for up to 30 bilayers. The slopes in Fig. 2 represent the mean amount of
coated DT-AF488 and TMC-RHO per bilayer, being 334.1 ng/bilayer
(R2 = 0.9963) for DT-AF488 and 251.5 ng/bilayer (R2 = 0.9983) for
TMC-RHO. The coating was not linear in the ﬁrst layers, as demon-
strated by the intersect with the y-axis, which is −543.8 ng and
−89.0 ng for DT-AF488 and TMC-RHO, respectively. After 30 bilayers
of DT-AF488/TMC-RHO were coated, 9.67 (± 0.51) μg DT-AF488 and
7.58 (± 0.38) μg TMC-RHO were cumulatively coated onto the mi-
croneedle arrays. Therefore, the ratio of coated DT to TMC was 1.3:1.
Furthermore, a coating of 5 bilayers of ﬂuorescently labeled DT-AF488/
TMC-RHO resulted in a coated amount of 1.20 (± 0.09) μg DT-AF488,
while a coating of 5 bilayers of DT/TMC resulted in a coated amount of
2.08 (± 0.14) μg DT. These results indicate that DT is coated more
eﬃciently onto the microneedle arrays than ﬂuorescently labeled DT-
AF488.
4.2. SEM and CLSM imaging of DT/TMC coated microneedle arrays
SEM imaging was performed to determine whether the microneedle
tip sharpness, geometry, and surface morphology of microneedles
coated with 5 bilayers of DT/TMC were maintained. As demonstrated in
Fig. 3A and B, a similar geometry with a tip diameter of< 1 μm and
Table 2
Immunization study with DT/TMC coated microneedle arrays.
Immunization route Application method Group name DT dose (μg)
D Coated MN array 2 bilayers
DT/TMC
0.05a
5 bilayers
DT/TMC
0.3a
10 bilayers
DT/TMC
0.6a
ID Single hollow MN ID DT control 0.31
ID DT/TMC
control
0.31 (+0.31 μg
TMC)
SC Conventional 26G
hypodermic needle
SC DT
control
0.31
DT-ALUMb 5 (+150 μg
AlPO4)
PBS pH 7.4c 0
The study parameters of the various immunization groups are summarized below. The
following abbreviations are used. D: dermal, ID: intradermal, MN: microneedle, SC:
subcutaneous.
a As determined by the amount of DT delivered from microneedle arrays coated with
ﬂuorescently labeled DT-IRDYE800/TMC into ex vivo mouse skin.
b DT adjuvanted with aluminum phosphate (as positive control).
c PBS pH 7.4 mock treated group (as negative control).
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surface morphology were obtained for both plain and coated micro-
needles.
To visualize the distribution of DT and TMC over the surface of DT/
TMC coated microneedles, CLSM imaging was performed on micro-
needles coated with 5 bilayers of ﬂuorescently labeled DT-AF488/TMC-
RHO. As demonstrated in Fig. 3C, DT-AF488 and TMC-RHO were in-
deed both coated onto the microneedles.
4.3. Antigenicity and structural integrity of coated DT
To assess whether coated DT remained antigenic, DT or ﬂuores-
cently labeled DT-AF488 released in vitro from 4 microneedle arrays
coated with 5 bilayers of DT/TMC or DT-AF488/TMC-RHO, was ex-
amined by DT-speciﬁc ELISA or ﬂuorescence measurements,
respectively. The release of DT and DT-AF488 (amount released/
amount coated * 100%) from the coated microneedle arrays was similar
at 28.5% (± 0.5) and 29.0% (± 2.0) (mean ± SEM), respectively,
suggesting that the antigenicity of coated and released DT was pre-
served.
Non-reducing SDS-PAGE was performed to determine the structural
integrity of the coated DT. Fluorescently labeled DT-AF488 released in
vitro from microneedle arrays coated with 30 bilayers of DT-AF488 and
TMC-RHO was analyzed together with control samples of DT-AF488
diluted from stock solution and a mixture of DT-AF488 and TMC-RHO
taken from stock solutions. The molecular weight of the coated and
released DT-AF488 was comparable to that of the DT-AF488 control
samples. Moreover, no bands indicative of fragments or covalent ag-
gregates were observed (data not shown).
Altogether, these results indicate that DT retained its structural in-
tegrity and antigenicity after it was released from the microneedle
surfaces.
4.4. Visualization of ﬂuorescently labeled DT-AF488/TMC-RHO delivery
into human skin
To examine whether ﬂuorescently labeled DT-AF488 and TMC-RHO
can be delivered into skin from coated microneedle arrays, microneedle
arrays coated with 5 bilayers of DT-AF488/TMC-RHO were applied by
impact-insertion and held in ex vivo human skin for 90 min.
Immediately after withdrawal of the coated microneedles, CLSM ima-
ging of the skin at the injection site was performed. From the image in
Fig. 3D, showing ﬂuorescence in the conduits in the skin from both DT-
AF488 (green) and TMC-RHO (red), it is clear that DT-AF488 and TMC-
RHO were successfully delivered into the skin after application and
withdrawal of the DT-AF488/TMC-RHO coated microneedle array.
4.5. Quantiﬁcation of dermally-delivered DT
To quantitatively determine the amount of DT delivered by DT/
TMC coated microneedle arrays into the skin, microneedle arrays
coated with 5 bilayers of ﬂuorescently labeled DT-IRDYE800/TMC
were used. Initially, ex vivo human skin studies were conducted to de-
termine the eﬀect of the application period of DT/TMC coated
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Fig. 2. Coating 30 bilayers of ﬂuorescently labeled DT-AF488 and TMC-RHO.
Cumulative amounts of coated ﬂuorescently labeled DT-AF488 and TMC-RHO by ap-
plying 30 DT-AF488/TMC-RHO bilayers onto microneedle arrays via a layer-by-layer
coating approach. The mean cumulative amounts ± SEM of DT-AF488 (green dots) and
TMC-RHO (red squares) coated onto the microneedle array are presented as a function of
the number of coated DT-AF488/TMC-RHO bilayers (n= 14). (For interpretation of the
references to colour in this ﬁgure legend, the reader is referred to the web version of this
article.)
Fig. 3. SEM and CLSM imaging of DT/TMC coated micro-
needle arrays.
Representative SEM images of plain microneedles (A) and
microneedles coated with 5 bilayers of DT/TMC (B) at
600× magniﬁcation, size bars represent 100 μm.
Representative CLSM images of (C) microneedles coated
with 5 bilayers of ﬂuorescently labeled DT-AF488 and
TMC-RHO (10× objective) and (D) DT-AF488 and TMC-
RHO that are released into ex vivo human skin, after mi-
croneedles coated with 5 bilayers of ﬂuorescently labeled
DT-AF488 and TMC-RHO were applied and held in the skin
for 90 min and subsequently removed before imaging (4×
objective). The images are overlays of DT-AF488 ﬂuores-
cence represented in green and TMC-RHO ﬂuorescence re-
presented in red. (For interpretation of the references to
colour in this ﬁgure legend, the reader is referred to the
web version of this article.)
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microneedle arrays on the amount of dermally-delivered DT. After ap-
plication periods of 30 and 90 min, 184 (± 16) ng and 293 (± 46) ng
DT were delivered, respectively. Because a 90 minute application
period was superior in comparison to a 30 minute application period, a
90 minute application period was used in subsequent studies.
As the immunization studies with DT/TMC coated microneedle ar-
rays were carried out in mice, subsequent studies were performed on ex
vivo mouse skin. To determine how the amount of dermally-delivered
DT depends on the number of coated DT/TMC bilayers, the amount of
dermally-delivered DT by microneedle arrays coated with either 1, 2, 5,
10 or 20 bilayers of ﬂuorescently labeled DT-IRDYE800/TMC was
quantiﬁed. The amount of dermally-delivered DT-IRDYE800 was line-
arly dependent on the number of bilayers coated onto the microneedle
arrays, as shown in Fig. 4. The slope coeﬃcient for DT-IRDYE800 de-
livery into ex vivo mouse skin was 67.5 ng/layer with a R2 of 0.9967.
4.6. Dose-response study of intradermally- and subcutaneously-delivered
DT
To determine the required amount of dermally-delivered DT for the
induction of DT-speciﬁc immune responses, a dose-response study was
performed. DT was delivered intradermally by using a single hollow
microneedle or subcutaneously by a conventional 26G hypodermic
needle. The DT-speciﬁc IgG responses after the 2nd booster im-
munization are presented in Fig. 5A (for responses after prime and 1st
booster immunization and IgG1:IgG2a ratios see Supplementary data
S5). As shown in Fig. 5A, after the 2nd booster immunization, the
midpoint (EC50) of the intradermal curve (37 ng) was signiﬁcantly
lower (± 3-fold) than the subcutaneous curve (116 ng). This indicated
that higher DT-speciﬁc IgG titers using lower DT doses are to be ex-
pected from intradermal immunization as compared to subcutaneous
immunization. With regard to dose selection, although a DT dose of
0.02 μg already resulted in DT-speciﬁc IgG responses, a 0.3 μg dose
resulted in similar responses as a 5 μg dose (16.6-fold lower). Moreover,
as shown in Fig. 5B, a minimum DT dose of 0.3 μg was required for DTx
neutralization titers, whilst a 0.78 μg dose resulted in similar DTx
neutralization titers in comparison to a 5 μg dose (6.4-fold lower).
Therefore, a minimum dose of 0.3 μg DT is required to be delivered by
DT/TMC coated microneedle arrays to induce potent DT-speciﬁc IgG
titers and DTx neutralization responses.
4.7. Immunization study with DT/TMC coated microneedle arrays
To study the potential to induce immunization of dermally-deliv-
ered DT by DT/TMC bilayer coated microneedle arrays, the DT-speciﬁc
immune responses as a function of the number of DT/TMC bilayers (2, 5
and 10) coated onto the microneedle arrays was investigated in an
immunization study. As 0.3 μg DT is required to induce DT-speciﬁc
immune responses upon intradermal immunization (based on results of
the dose-response study), microneedle arrays should be coated with at
least 5 DT/TMC bilayers (see delivery studies in ex vivo skin).
The DT-speciﬁc IgG titers increased with an increasing number of
coated DT/TMC bilayers after every subsequent immunization (prime,
boost and 2nd boost), as shown in Fig. 6A–C. The higher response
owing to immunization with an increased number of coated DT/TMC
bilayers was also reﬂected in the DTx neutralization titers after the 2nd
boost immunization, as shown in Fig. 6D. After every subsequent im-
munization, DT-speciﬁc IgG titers and DTx neutralization titers re-
sulting from dermal immunization with microneedle arrays coated with
10 bilayers of DT/TMC (corresponding with approximately 0.6 μg de-
livered DT) and subcutaneous immunization with 5 μg DT-ALUM were
not signiﬁcantly diﬀerent. The addition of TMC to the DT formulation
for intradermal immunization with a single hollow microneedle did not
result in increased DT-speciﬁc responses. As demonstrated in Fig. 6E, a
stepwise decrease in IgG1:IgG2a ratio was observed for immunization
by microneedle arrays coated with 2, 5 and 10 bilayers of DT/TMC.
DT-speciﬁc responses resulting from subcutaneous immunization
with or without anesthesia were similar (data not shown), demon-
strating that anesthesia had no eﬀect on the DT-speciﬁc immune re-
sponses. PBS pH 7.4 mock treatment did not result in any DT-speciﬁc
IgG titers.
Upon comparing immunization routes, dermal immunization with
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Quantiﬁcation of the amount of ﬂuorescently labeled DT-IRDYE800 (mean ± SEM,
n= 3) dermally delivered into ex vivo mouse skin by microneedle arrays coated with an
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Fig. 5. A dose-response study of DT delivered into the skin.
DT-speciﬁc immune responses as a result of intradermal (ID) and subcutaneous (SC)
delivery of doses ranging from 0.02 to 5 μg after the 2nd boost immunization. The DT-
speciﬁc IgG midpoint titers (A) and DTx neutralization titers (B) are represented by blue
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microneedle arrays coated with 5 or 10 DT/TMC bilayers or in-
tradermal immunization with a single hollow microneedle resulted in
higher DT-speciﬁc IgG titers in comparison to subcutaneous im-
munization after the prime and boost immunization. The DT-speciﬁc
IgG titers of dermal or intradermal and subcutaneous immunization
were only comparable after the 2nd boost immunization. These results
indicate that dermal or intradermal immunization resulted in a faster
development of IgG responses than subcutaneous immunization. A si-
milar trend was observed for the DTx neutralization titers.
5. Discussion
In this study, it was demonstrated that the DT/TMC layer-by-layer
coating approach on pH-sensitive high-density microneedle arrays of-
fers a tunable vaccine delivery system. The amount of DT that was
coated and delivered into the skin was reproducible and could be tuned
by selecting the number of coated DT/TMC bilayers. Moreover, dermal
immunization of mice by using the DT/TMC coated microneedle arrays
resulted in strong functional DT-speciﬁc immune responses.
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Fig. 6. Immunization study with DT/TMC coated microneedle arrays.
Assessment whether DT/TMC coated microneedle arrays induce DT-speciﬁc immune responses, in which a microneedle array coated with an increasing number of DT/TMC bilayers is
applied onto the skin and compared to intradermal and subcutaneous control groups (see Table 2). Presented are the DT-speciﬁc IgG midpoint titers 21 days past prime immunization (A),
boost immunization (B) and 2nd boost immunization (C) resulting from DT immunization via the dermal route by a DT/TMC coated microneedle array (coated MN, green triangles or
bars), intradermal route by a single hollow microneedle (ID, blue circles or bars) or subcutaneous route by a conventional 26G hypodermic needle (SC, purple squares or bars). DTx
neutralization titers (D) and IgG1:IgG2a ratios (E) were determined in serum at 21 days past the 2nd boost immunization as well. Black lines and bars represent mean ± 95% conﬁdence
interval (n= 8) and stars represent a signiﬁcant increase (p < 0.05). (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this
article.)
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5.1. DT/TMC layer-by-layer coating approach for high-density microneedle
arrays
The amount of coated DT or TMC incremented linearly with each
increasing bilayer of DT/TMC coated onto the microneedle arrays. This
was also observed for coating IPV and TMC onto high-density micro-
needle arrays utilizing a similar layer-by-layer coating approach [24].
This demonstrates that a layer-by-layer coating procedure onto pH-
sensitive microneedles is a versatile method to precisely control the
amount of coated antigen by selecting the number of coated bilayers.
Furthermore, this coating procedure may be applicable, not only to
proteins, but also to nanoparticles.
Moreover, the microneedle tips of microneedles coated with 5 bi-
layers of DT/TMC had a tip diameter< 5 μm, which is required for
eﬀortless skin penetration [28]. Coating high-density microneedle ar-
rays while preserving sharp microneedle tips is possible, by using this
layer-by-layer coating approach or a nitrogen jet drying coating ap-
proach [17,29], while dip-coating approaches resulted in blunt micro-
needle tips [15,17–19]. Furthermore, viscosity enhancers, lyoprotec-
tants or surfactants are not required for this layer-by-layer coating
approach, which simpliﬁes the formulation, while coating a high
amount of antigen in a thin layer onto the microneedle arrays.
5.2. Delivery of DT/TMC into the skin by DT/TMC coated microneedle
arrays
Using CLSM, we demonstrated that the DT and TMC delivered by
DT/TMC coated microneedle arrays were co-localized in the conduits in
the skin, but this method is not suitable to quantify the amount of DT
within the skin. For this reason, we measured the near-infrared ﬂuor-
escence intensity in the skin of DT-IRDYE800 delivered by the coated
microneedle arrays.
Although precise dosing has been considered critical in dermal
immunization [13,14], it only has been convincingly addressed in a
limited number of studies [30–32]. In the current study, we demon-
strate that a linear increase in coated DT with an increasing numbers of
DT/TMC bilayers also resulted in a linearly increased amount of DT
delivered into skin, allowing to select a precise dose that is reproducibly
delivered into the skin. The delivery eﬃciency (amount released/
amount coated onto the microneedle array * 100%) of 16.7% in ex vivo
mouse skin was comparable to that reported (between 7.6 and 37.5%)
for other dry coating approaches for high-density microneedle arrays
[29,32–35].
5.3. Immunization studies
5.3.1. Coated microneedle arrays
Dermal immunization by microneedle arrays coated with 10 DT/
TMC bilayers led to similar DT-speciﬁc immune responses compared
with subcutaneous immunization by 5 μg DT-ALUM. The dose delivered
in the skin by these coated microneedle arrays was determined at about
0.6 μg, i.e., about 8-fold lower than the subcutaneous dose. Moreover,
coated microneedle arrays are easier to use for (intra-)dermal im-
munization compared to hollow microneedles, which require a so-
phisticated applicator [14]. Additionally, dry vaccine formulations
generally are more stable than liquid ones [14,15,18,33]. Altogether,
this demonstrates the potential of antigen-coated microneedle arrays as
an alternative for subcutaneous immunization.
The accuracy at which the DT dose was delivered in the skin by
selecting an increasing number of DT/TMC bilayers coated onto the
microneedle arrays was reﬂected in the corresponding increasing levels
of DT-speciﬁc immune responses. For example, dermal immunization
with microneedle arrays coated with 5 bilayers of DT/TMC, corre-
sponding with a DT dose of 0.3 μg delivered into the skin, resulted in
similar DT-speciﬁc immune responses as intradermal immunization
with 0.3 μg DT delivered by a single hollow microneedle.
5.3.2. Application mode of the DT/TMC coated microneedle arrays
A supposed drawback of coated microneedle arrays is the lengthy
application period of 90 min in the skin to deliver a suﬃcient amount of
antigen. For this reason, in a pilot study a short-lasting repetitive ap-
plication mode was investigated to strongly reduce the required ap-
plication time. By using the impact insertion applicator system, mi-
croneedle arrays coated with 5 bilayers of DT/TMC were repeatedly
applied onto the skin for 10 applications at a frequency of 1 Hz (1
application per second, 10 s total, with an application time of 0.5 s per
application). Intriguingly, 10 repeated applications in 10 s resulted in
similar DT-speciﬁc immune responses as a single 90 minute application
(Supplementary data S7). Therefore, this application mode permits very
short application times, which may increase the attractiveness of the
use of coated microneedle arrays even more, from a patient compliance
perspective.
5.3.3. Inﬂuence of TMC
TMC was used as a poly-cation to enable layer-by-layer coating (as
DT is negatively charged at coating pH) and because it has been re-
ported to enhance DT-speciﬁc immune responses upon intradermal
immunization [26]. However, in the current study only a mild increase
in DT-speciﬁc immune responses (not signiﬁcant) was observed, likely
because much lower DT and TMC doses were used.
5.3.4. Intradermal versus subcutaneous immunization
It became evident in both immunization studies that (intra-)dermal
immunization is more eﬃcient at inducing DT-speciﬁc immune re-
sponses at low doses as compared to subcutaneous immunization. This
high immunization eﬃciency at low antigen doses could lead to dose-
sparing and thereby cost reduction of vaccination programs, which is
especially of interest to low-income countries [36].
For both intradermal and subcutaneous immunization, humoral
immune responses were dominant over cellular immune responses. This
is represented by a high IgG1:IgG2a ratio, as humoral immune re-
sponses are characterized by the production of IgG1 antibodies, and
cellular immune responses are characterized by the production of IgG2a
antibodies [37,38]. Surprisingly, in contrast to subcutaneous im-
munization (less dominant humoral immune responses at low antigen
doses), upon intradermal immunization the humoral immune responses
became predominant at low antigen doses in a dose-dependent manner.
6. Conclusion
In this study, we examined a layer-by-layer coating approach to coat
high-density microneedle arrays with DT as anionic antigen and TMC as
counter poly-cation and adjuvant. This coating approach allowed to
control the amount of DT coated onto the microneedle arrays and de-
livered into the skin, whilst maintaining tip sharpness and integrity of
the coated DT. After studying dose-response of DT immunization via the
intradermal and subcutaneous route, it was demonstrated that in-
tradermal immunization at low DT doses resulted in superior immune
responses compared to subcutaneous immunization. Furthermore, we
have demonstrated that immunization by DT/TMC coated microneedle
arrays induced strong DT-speciﬁc immune responses. Summarizing, the
layer-by-layer coating approach onto pH-sensitive microneedles is a
versatile method to precisely control the amount of microneedle-coated
and dermally-delivered antigen, which is highly-suitable for dermal
immunization.
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